John Alexander Kelly - 17 Feb 2026 Form 4 Insider Report for PRECISION BIOSCIENCES INC (DTIL)

Role
Chief Financial Officer
Signature
/s/ Dario Scimeca, Attorney-in-fact for John Alexander Kelly
Issuer symbol
DTIL
Transactions as of
17 Feb 2026
Net transactions value
-$31,292
Form type
4
Filing time
19 Feb 2026, 16:31:00 UTC
Previous filing
22 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kelly John Alexander Chief Financial Officer C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM /s/ Dario Scimeca, Attorney-in-fact for John Alexander Kelly 19 Feb 2026 0001590030

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DTIL Common Stock Options Exercise $0 +27,584 +26% $0.000000 134,032 17 Feb 2026 Direct F1, F2
transaction DTIL Common Stock Sale $31,292 -8,149 -6.1% $3.84 125,883 18 Feb 2026 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DTIL Restricted Stock Units Options Exercise $0 -27,584 -33% $0.000000 55,166 17 Feb 2026 Common Stock 27,584 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the vesting of Restricted Stock Units ("RSUs") on February 17, 2026.
F2 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3 The sales were effected pursuant to a Rule 10b5-1 plan adopted on January 17, 2025. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.
F4 RSUs vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.